In this article, Dr Daniel Heng focuses on prognostic criteria (IMDC in particular), first and second line therapy, and the future of prognostic biomarkers for the management of kidney cancer. Dr Heng was presenting at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week.

Read more in UroToday here